Skip to main content
 

2014 Press Releases

Webcast ImageWebcast
Idera Pharmaceuticals, Inc. at Piper Jaffray Healthcare Conference  (Replay)
12/03/14 at 3:30 p.m. ET
Idera Pharmaceuticals, Inc. at Piper Jaffray Healthcare Conference
Wednesday, December 3, 2014 3:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
12/15/14Idera Announces Several Key Additions to Management Team
CAMBRIDGE, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed J. Peter Wolf as Senior Vice President, General Counsel and Elizabeth Eberhardt as Vice President, Oncology Team. Vincent J. Milano, Chief Executive Officer of Idera Pharmaceuticals, stated, "Both Pete and Liz bring tremendous experience to Idera and immedia... 
Printer Friendly Version
12/08/14Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting
- Clinical safety data for IMO-8400 support dose escalation in ongoing Phase 1/2 trials - Preclinical data show promise of early-line combination therapy with IMO-8400 and rituximab CAMBRIDGE, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced that data for its lead product candidate IMO-8400 were presented at the 56th... 
Printer Friendly Version
12/02/14Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent and Systemic Anti-Tumor Activity in Preclinical Models
Data Highlight Potential Opportunity to Enhance Activity of Emerging Class of Checkpoint Inhibitors With Idera's Proprietary Toll-Like Receptor Agonists CAMBRIDGE, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2055 and ipilimumab de... 
Printer Friendly Version
12/02/14Idera Announces Appointment of Robert A. Doody Jr. as Vice President of Investor Relations and Corporate Communications
CAMBRIDGE, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations and Corporate Communications. Vincent J. Milano, Chief Executive Officer of Idera Pharmaceuticals, stated, "I am thrilled to have the opportunity to work with Bob again. Bob has tremendous credibility ... 
Printer Friendly Version
12/02/14Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for cancer and rare diseases, today announced that Company management will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 3:30 p.m. EST in New York. A live audio webcast of the presentation will be available in the Investors and Media section of Idera's website at h... 
Printer Friendly Version
12/01/14Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer
-- Appointment brings commercial, operational and financial expertise -- Will build the business to advance programs in cancer and rare diseases -- Dr. Sudhir Agrawal to continue to lead scientific research CAMBRIDGE, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed Vincent J. Milano as Chief Executive Office... 
Printer Friendly Version
11/13/14Idera Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for rare diseases, today announced that Company management will present at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 4:10 p.m. EST in New York. A live audio webcast of the presentation will be available in the Investors and Media section of Idera's website at www.iderapharma.com or a... 
Printer Friendly Version
11/07/14Idera Pharmaceuticals Reports Third Quarter Financial Results and Announces Expansion of Rare Disease Development Portfolio
-- Enrollment achieved in first two dose cohorts of Phase 1/2 Waldenstrom's trial -- Myositis program advanced with specification of Phase 2 clinical trial plan in dermatomyositis -- Rare disease portfolio expanded to include Duchenne muscular dystrophy; collaboration with leading Duchenne patient group announced CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics... 
Printer Friendly Version
11/07/14Idera Pharmaceuticals and Parent Project Muscular Dystrophy Announce Collaboration to Advance New Treatment Approach for Duchenne Muscular Dystrophy
Toll-like receptor antagonism designed to treat muscle inflammation central to disease progression New approach offers potential to treat broad population of patients regardless of their genetic mutation CAMBRIDGE, Mass. and HACKENSACK, N.J., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals (Nasdaq:IDRA) and Parent Project Muscular Dystrophy (PPMD) today announced a collaboration to advance Idera's proprietary Toll-like receptor (TLR) technology for the treatment of Duchenne mu... 
Printer Friendly Version
11/06/14Idera Pharmaceuticals Announces Upcoming Presentations of Data From Oncology Programs at Key Scientific Meetings
CAMBRIDGE, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today announced the following data abstracts from its oncology programs were accepted for presentation at upcoming scientific meetings. 56th Annual Meeting of the American Society of Hematology December 6-9, 2014; San Francisco, Calif. IMO-8400, an Antagonist of Toll-like Receptors 7, 8, and 9... 
Printer Friendly Version
10/29/14Idera Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Corporate Update on November 7, 2014
CAMBRIDGE, Mass., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with rare diseases, today announced that the Company will host a conference call and live audio webcast at 8:00 a.m. EST on Friday, November 7, 2014 to report its third quarter 2014 financial results and provide an update on recent business activities. The live webcast can be accessed under "Investor Events... 
Printer Friendly Version
10/14/14Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200
- IND application for Phase 1 clinical trial of IMO-9200 in healthy volunteers accepted by FDA; patient dosing on track to begin in fourth quarter - New IMO-9200 data presented at 10th Annual Meet ing of the Oligonucleotide Therapeutics Society demonstrate inhibition of TLR-mediated immune responses in multiple preclinical models CAMBRIDGE, Mass., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid the... 
Printer Friendly Version
08/12/14Idera Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Corporate Update
Phase 2 clinical programs progressing in two genetically targeted lymphoma indications New partnerships with myositis and GvHD communities further upcoming clinical development programs CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 12, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today reported financial and operational results for the ... 
Printer Friendly Version
08/07/14Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis
CAMBRIDGE, Mass. & ALEXANDRIA, Va.--(BUSINESS WIRE)--Aug. 7, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach f... 
Printer Friendly Version
08/06/14Idera Pharmaceuticals and Collaborators Publish Promising Preclinical Data Targeting microRNA with Gene Silencing Oligonucleotide Technology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced the publication of promising preclinical data demonstrating the application of the Company’s novel Gene Silencing Oligonucleotides (GSOs) to inhibit microRNAs implicated in neovascularization, a process that involves the ... 
Printer Friendly Version
08/05/14Idera Pharmaceuticals to Host Conference Call and Webcast to Report Second Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and orphan diseases, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Tuesday, August 12, 2014 to report its second quarter 2014 financial results and provide a corporate update. In order t... 
Printer Friendly Version
06/27/14Idera Pharmaceuticals to be Added to the Russell 3000® and Russell 2000® Indexes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 27, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing nucleotide therapeutics for patients with cancer and orphan diseases, today announced that it will be added to the Russell 3000® and Russell 2000® Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 27, 2014, according to a preliminary list ... 
Printer Friendly Version
06/17/14Idera Pharmaceuticals to Participate in a Panel Discussion at the Piper Jaffray GenomeRx Symposium
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleotide therapeutics for patients with cancer and orphan diseases, today announced that Sudhir Agrawal, D. Phil., Chief Executive Officer, will participate in a panel discussion entitled “RNA/DNA: Getting It Where You Need It” at the Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014. The panel ... 
Printer Friendly Version
06/13/14Idera Pharmaceuticals to Present at the Nucleic Acid Summit 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 13, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today announced that Walter Strapps, Ph.D., Executive Director of RNA Therapeutics, will present at the Nucleic Acid Summit 2014 in San Diego, California on Thursday, June 19, 2014 at 4:15 p.m. PDT. The title of Dr. Strapps’ presentation is "Gene Silencing... 
Printer Friendly Version
05/28/14Idera Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today announced that Company management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 8:30 a.m. EDT in New York City. A live audio webcast of the presentation will be available in the Investors ... 
Printer Friendly Version
05/13/14Idera Pharmaceuticals Reports First Quarter 2014 Financial Results and Provides Update on Key Programs and Business Strategy
- Strengthened leadership team in development and commercialization for orphan drugs – - Initiated clinical development in Waldenström’s and DLBCL patients - - Presented promising preclinical data in genetically defined forms of B-cell lymphoma - - Entered into collaboration with Abbott for companion diagnostic - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical sta... 
Printer Friendly Version
05/08/14Idera Announces Agreement with Abbott to Develop a Companion Diagnostic for IMO-8400 in Genetically Defined Forms of B-cell Lymphoma
- IMO-8400 is in clinical development for the potential treatment of two genetically defined forms of B-cell lymphoma characterized by the presence of the oncogenic mutation MYD88 L265P – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotechnology company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced today tha... 
Printer Friendly Version
05/06/14Idera Pharmaceuticals to Host Conference Call and Webcast to Report First Quarter 2014 Financial Results and Provide a Detailed Pipeline Review
- Company to Review Pipeline of Orphan Therapeutic Candidates, Business Strategy and Recent Highlights - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced that the Company will host a conference call and live audio webcast with an accompa... 
Printer Friendly Version
05/05/14Idera Expands Management Team with Three Key Hires
- Expansion Supports Rapid Development of Novel Drug Pipeline in Oncology and Orphan Diseases - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced the addition of three new management team members to support the Company’s progress in its d... 
Printer Friendly Version
04/07/14Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation
- Data supports TLR antagonism as potential therapeutic approach for genetically defined forms of B-cell lymphoma – - IMO-8400 in Phase 1/2 trial for Waldenström’s macroglobulinemia – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 7, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today presented new preclinical data demonstrating the ability of its Toll-like receptor (TLR) antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L26... 
Printer Friendly Version
03/28/14Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
Trial meets primary objective of demonstrating safety and tolerability over 12-week treatment period IMO-8400 also demonstrates clinical proof-of-concept in psoriasis CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. Th... 
Printer Friendly Version
03/13/14Idera Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results and Provides Corporate Update
- Clinical advancements in autoimmune diseases and genetically defined forms of B-cell lymphoma - - Details announced for planned clinical development of IMO-8400 in polymyositis and dermatomyositis – - Plans announced to identify drug candidates from its gene silencing oligonucleotide platform - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceuti... 
Printer Friendly Version
03/13/14Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases
- Company to initiate clinical development of IMO-8400 in polymyositis and dermatomyositis in first half of 2014 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today announced that it plans to initiate clinical development... 
Printer Friendly Version
03/12/14Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 12, 2014-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments’ Julian C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors, effective March 10, 2014. Founded in 2000, Baker Brothers Investment... 
Printer Friendly Version
03/06/14Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial res... 
Printer Friendly Version
02/26/14Idera to Present at the Cowen & Co. 34th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the Cowen & Co. 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10:00 a.m. EST at the Boston Marriott Copley ... 
Printer Friendly Version
02/18/14Idera to Present at the 2014 RBC Capital Markets’ Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 18, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets’ Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hote... 
Printer Friendly Version
02/10/14Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”) today announced the closing of its previously announced underwritten public offering of 7,867,438 shares of common stock at an offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at an offering price of $3.99 per pre-funded warrant, which is the per share public ... 
Printer Friendly Version
02/06/14Idera to Present at 16th Annual BIO CEO & Investor Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. ... 
Printer Friendly Version
02/05/14Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”) today announced the pricing of an underwritten public offering of 6,841,250 shares of common stock for a public offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at the per share public offering price for the common stock less the $0.01 per share exercise price ... 
Printer Friendly Version
02/04/14Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Cowen and Company, LLC are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and th... 
Printer Friendly Version
01/22/14Idera Announces Publication of New Data Demonstrating Impact of Inhibiting TLRs 7, 8, and 9 in a Preclinical Model of Autoimmune Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2014-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced the publication of a study supporting the potential role of the suppression of Toll-like-receptors (TLRs) 7, 8, and 9 in the treatment of psoriasis. The data were published ... 
Printer Friendly Version
01/09/14Idera Expands Leadership Team and Strengthens Clinical Development Expertise in Oncology and Orphan Diseases
Chief Medical Officer Lou Brenner, MD, and New Board Member Mark Goldberg, MD, to help guide clinical development strategy and execution CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2014-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that it has strengthened its clin... 
Printer Friendly Version

Contact

Please direct all general questions regarding Idera to:

Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge, MA 02139

617-679-5500 tel
617-679-5592 fax

info@iderapharma.com